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Abstract 17 
Worldwide, 3 billion people are at risk of hookworm infection, particularly in resource-poor 18 
countries. While control of soil-transmitted helminthiases relies mostly on chemotherapy, only 19 
few drugs are available and concern about potential emergence of drug resistance is rising. 20 
In the present study, tribendimidine, a derivative of amidantel, and its metabolites deacylated 21 
amidantel (dADT) and acetylated deacylated amidantel (AdADT) were tested in vitro and in 22 
vivo against Heligmosomoides bakeri and Ancylostoma ceylanicum, two hookworm rodent 23 
models, alone or in combination with standard drugs. 24 
Tribendimidine achieved IC50s ≤ 5 µg/ml against both H. bakeri third-stage larvae and adults 25 
in vitro and a single 2 mg/kg oral dose resulted in complete worm elimination in vivo. 26 
Comparable results were obtained with dADT, whereas AdADT displayed no effect in vitro 27 
and gave a moderate worm burden reduction of 42 % in H. bakeri-infected mice. 28 
Tribendimidine combined with albendazole, levamisole or ivermectin revealed antagonistic 29 
interactions against H. bakeri in vitro and no significant killing effect in vivo. Tribendimidine 30 
and dADT exerted high efficacies against A. ceylanicum third-stage larvae (IC50s <0.5 µg/ml) 31 
whereas adults were moderately affected in vitro (IC50s > 88 µg/ml). In vivo at single oral 32 
doses of 10 mg/kg, dADT showed a slightly higher efficacy than tribendimidine, achieving 33 
worm burden reductions of 87.4 % and 74.8 %, respectively. At the same dose, AdADT 34 
reduced the worm burden by 57.9 %. Synergistic interactions were observed with 35 
tribendimidine-levamisole combinations against A. ceylanicum in vitro (combination index at 36 
IC50 = 0.5), and in vivo (combination index at ED90 = 0.19). In conclusion, tribendimidine and 37 
dADT show potent anti-hookworm properties. The potential of the promising tribendimidine-38 
levamisole combination should be investigated in greater detail.   39 
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1. Introduction 45 
 Hookworms are intestinal parasitic nematodes of great public health significance. 46 
Necator americanus and Ancylostoma duodenale are the two most important species 47 
infecting humans. They occur mainly in Sub-Saharan Africa, South-East Asia, China and in 48 
the Pacific Islands. More than 3 billion people are at risk of acquiring hookworm infections 49 
(de Silva et al., 2003). Hookworm infection is one of the so-called neglected diseases, 50 
affecting particularly people living in resource-poor settings (Hotez et al., 2007). Disease 51 
morbidities depend directly on the infection intensity, ranging from asymptomatic cases to 52 
anaemia, nutrient loss and profound physical and mental deficits (Hotez et al., 2004; Roche 53 
and Layrisse, 1966; Stoltzfus et al., 1997). The current mainstay to control hookworm 54 
infections is chemotherapy administered in the framework of periodic mass drug 55 
administration campaigns, targeting high-risk groups (Harhay et al., 2010; Hotez, 2008). Only 56 
4 drugs are currently recommended by the World Health Organisation (WHO) against soil-57 
transmitted helminthiases: albendazole, mebendazole, levamisole and pyrantel pamoate 58 
(Keiser and Utzinger, 2010), all of them in use for decades (Holden-Dye and Walker, 2007; 59 
Hotez et al., 2006; Utzinger and Keiser, 2004). 60 
Since resistance to these drugs has spread widely in livestock (Kaplan, 2004), there is rising 61 
concern about potential emergence of resistance among human nematode populations 62 
(Albonico et al., 2003; De Clercq et al., 1997; Geerts and Gryseels, 2001; Reynoldson et al., 63 
1997). New drugs are therefore urgently needed, and combinations of existing drugs have to 64 
be thoroughly explored to prevent emergence of drug resistance (Barnes et al., 1995; Nyunt 65 
and Plowe, 2007; van den Enden, 2009). 66 
Tribendimidine, a successor of a drug developed by Bayer, amidantel (Bay d 8815), was 67 
discovered in the 1980s by the Institute of Parasitic Diseases in Shanghai, China (Xiao et al., 68 
2005). Tested against a range of helminths in the laboratory and in humans, a promising 69 
broad-spectrum activity, rapid onset of action and good tolerability were documented (Keiser 70 
et al., 2007; Keiser et al., 2008; Steinmann et al., 2008; Xiao et al., 2005). In humans, 71 
tribendimidine showed excellent efficacy against hookworms (Necator americanus and 72 
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Ancylostoma duodenale), performing even better than albendazole, the current drug of 73 
choice (Xiao et al., 2005). The Chinese authorities approved tribendimidine for human use in 74 
2004 (Sun, 1999; Utzinger and Keiser, 2004).  75 
Like levamisole and pyrantel, tribendimidine belongs to the L-subtype nAChR (nicotinic 76 
acetylcholine receptor) agonists family (Hu et al., 2009). When administered in vivo, 77 
tribendimidine is rapidly metabolised into deacylated amidantel (dADT), which undergoes 78 
acetylation, resulting in acetylated deacylated amidantel (AdADT) (Xue et al., 2005; Xue et 79 
al., 2010). Tribendimidine and dADT exhibited high efficacies against Necator americanus in 80 
a hamster model, whereas AdADT showed only moderate effects, suggesting that dADT is 81 
the key metabolite for nematocidal activity (Xue et al., 2005; Xue et al., 2010). Tribendimidine 82 
was also found to be very potent against Ancylostoma caninum (Xiao et al., 2005). 83 
The aim of the present investigation was to study the in vitro and in vivo activities of 84 
tribendimidine and its metabolites dADT and AdADT against H. bakeri (formerly known as H. 85 
polygyrus) and A. ceylanicum, two hookworm laboratory animal models. In addition, we 86 
tested the combination dose effects of tribendimidine with albendazole, levamisole or 87 
ivermectin and evaluated them using combination indices. 88 
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2. Materials and methods 89 
2.1. Drugs 90 
 Tribendimidine (N,N'-bis(4-(1-dimethylamino)ethylideneaminophenyl)-1,4-phenylene 91 
dimethylidyneamine), MW: 452.594 g/mol, and the metabolites deacylated amidantel (dADT), 92 
MW: 173.214 g/mol, and acetylated deacylated amidantel (AdADT), MW: 215.251 g/mol, 93 
were donated by Shandong Xinhua Pharmaceutical Company (China) and stored at 4 °C. 94 
Albendazole, levamisole and ivermectin were purchased from Sigma-Aldrich (Buchs, 95 
Switzerland). For the in vitro studies, 10 mg/ml (H. bakeri) or 5 mg/ml (A. ceylanicum) stock 96 
solutions were prepared for all drugs in 100 % DMSO (Fluka, Buchs, Switzerland) and stored 97 
at 4 °C. For the in vivo studies, drugs were suspended in 7 % (v/v) Tween 80 % and 3 % 98 
(v/v) ethanol shortly before treatment. 99 
 100 
2.2. Animals 101 
Three week-old male Syrian Golden hamsters were purchased from Charles River 102 
(Sulzfeld, Germany). Four week-old female NMRI mice were purchased from Harlan (Horst, 103 
the Netherlands) or Charles River (Sulzfeld, Germany). All animals were kept in macrolon 104 
cages under environmentally-controlled conditions (temperature: 25 °C, humidity: 70 %, 105 
light/dark cycle 12/12 h) and had free access to water and rodent food (Rodent Blox from 106 
Eberle NAFAG, Gossau, Switzerland). They were allowed to acclimatize in the animal facility 107 
of the Swiss Tropical and Public Health Institute (Swiss TPH) for one week before infection. 108 
The current study was approved by the local veterinary agency based on Swiss cantonal and 109 
national regulations (permission no. 2070).  110 
 111 
2.3. Parasites and infections 112 
Ancylostoma ceylanicum third-stage larvae (L3) were kindly provided by Prof. Jerzy 113 
Behnke (University of Nottingham). The A. ceylanicum life cycle has been maintained at the 114 
Swiss TPH as described earlier (Garside and Behnke, 1989; Ray and Bhopale, 1972; Tritten 115 
et al., in press-b). Briefly, male Syrian gold hamsters were immunosuppressed with 116 
 6 
hydrocortisone (3 mg/kg, twice weekly) or dexamethasone (1 mg/l continuously in the 117 
drinking water) and infected orally at 4 weeks, with 150 L3 larvae. For in vivo studies, 118 
hamsters were not immunosuppressed and infected orally with 300 L3. Details on the life 119 
cycle of H. bakeri, maintained at the institute since 2009 have recently been described 120 
(Nwosu et al., 2011). Briefly, 4-week old NMRI mice were infected orally with 150 H. bakeri 121 
L3 (for in vitro studies), or only with 80 L3 (for in vivo work).   122 
 123 
2.4. In vitro studies 124 
The motility assay was used to evaluate drug susceptibilities of L3 and adult worms of 125 
A. ceylanicum and H. bakeri (Kopp et al., 2008a; Stepek et al., 2005). Drug effects on egg 126 
development were assessed observing embryonation and hatching. 127 
 128 
2.4.1. H. bakeri 129 
 In vitro assays with H. bakeri L3 were performed following procedures presented 130 
elsewhere (Nwosu et al., 2011). Briefly, in 24-well plates (Costar), 20 µl of a larval solution 131 
containing 30 freshly isolated H. bakeri L3 were added to 470 µl RPMI 1640 supplemented 132 
with 25 mM HEPES, 500 U/ml penicillin, 500 µg/ml streptomycin and 0.6 µg/ml amphotericin 133 
B. Ten µl drug solutions with appropriate drug concentrations were added, to reach final 134 
concentrations ranging from 100 to 0.1 µg/ml. The assays were incubated for 72 hours at 135 
room-temperature. For drug combination studies, the assay was performed in a total volume 136 
of 1 ml, with final drug concentrations of 1 or 0.1 µg/ml. Larval motility was assessed at 72 137 
hours microscopically (inverted microscope, Carl Zeiss, Germany, magnification 20x) 138 
following addition of hot water (~80 °C) and exposure to microscope light, and the 139 
percentage survival determined. Assays were conducted three times in duplicate.  140 
 Similarly, 4 adult worms (males and females, gained upon dissection of infected mice 141 
guts) were incubated in 48-well plates in 500 µl phenol-red free RPMI 1640 supplemented 142 
with HEPES and antibiotics, at 37 °C, 5 % CO2. The motility was assessed microscopically 143 
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(magnification 20x) 72 hours following drug exposure (final concentrations of 100 to 0.1 144 
µg/ml) and the viability determined. Assays were conducted at least twice.  145 
 The ovicidal activity of drugs was assessed following a slightly modified protocol by  146 
Fonseca-Salamanca et al. (Fonseca-Salamanca et al., 2003). Briefly, in 48-well plates 147 
(Costar), 20 µl egg solution containing 30 freshly isolated unembryonated eggs were added 148 
to 470 µl RMPI 1640, supplemented with HEPES and antibiotics. The test drugs (10 µl) at 149 
concentrations ranging from 100 to 1 µg/ml were added. The plates were incubated at room-150 
temperature. Twenty-four hours post-exposure, the eggs were examined microscopically 151 
(magnification 80-160x) for embryonation, and 40 hours post-incubation hatching was 152 
assessed. In all assays (L3, adults and eggs) control wells contained the highest DMSO 153 
concentration used in the tests (1 % v/v). 154 
 155 
2.4.2. A. ceylanicum 156 
Experiments were conducted as described recently (Tritten et al., in press-a). Briefly, 157 
30 L3 per well (96-well plates) were incubated for 72 hours at room-temperature in the 158 
presence of 200 μl HBSS medium (containing 25 µg/ml amphotericin B (Sigma-Aldrich) and 159 
1% (v/v) penicillin-streptomycin solution (10,000 U/ml penicillin and 10 mg/ml streptomycin, 160 
Sigma-Aldrich) and drug dilutions (ranging from 100 to 0.01 µg/ml). The larval motility was 161 
investigated using microscopy (magnification 20x) following addition of hot water (~80 °C) 162 
and exposure to microscope light. For combination chemotherapy experiments, 50 µl of the 163 
individual drug solutions were added to each well and serially diluted, in order to have final 164 
concentrations ranging from 4x IC50 to 0.25x IC50 for each drug.  165 
Drug susceptibilities of adult worms (obtained from hamster’s guts upon dissection) 166 
were tested in 48-well plates (Costar) with 3-4 worms per well containing 1 ml medium and 167 
drugs at 37 °C, 5 % CO2 for 72 hours. The motility was determined microscopically 168 
(magnification 20x) using a viability scale ranging from 2 (worms healthy, fit) and 0 (death).  169 
The ovicidal activity was evaluated using 50 freshly isolated eggs per well which were 170 
incubated in 1 ml deionised water containing 10 µg/ml of the test drug. After 24 hours, 20 171 
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eggs per well were examined microscopically (magnification 80-160x) for embryonation, and 172 
after 48 hours, 20 eggs were examined for hatching. In all assays (L3, adults and eggs) 173 
control wells contained the highest DMSO concentration used in the tests (max. 2 % v/v). 174 
 175 
2.5. In vivo studies 176 
2.5.1. H. bakeri 177 
 Six groups (n=4) of mice were treated orally with 0.5, 1 or 2 mg/kg single doses of 178 
tribendimidine, or 1 or 2 mg/kg single doses of dADT or AdADT, 21-28 days post-infection 179 
(p.i.). Untreated mice (2x n=4) served as controls. To assess the effect of drug combinations, 180 
0.5 mg/kg tribendimidine was combined with 10 mg/kg albendazole, 1.25 mg/kg levamisole 181 
or 0.125 mg/kg ivermectin, each dose being the estimated ED50 value for the single drug. 182 
Worms remaining in the gut on day 8 post-treatment were counted after killing the mice with 183 
the CO2 method. Worm burden reductions were calculated as following: [(a-b)/a]*100], where 184 
a = average worm count in the control group upon dissection and b = average worm count in 185 
a treated group upon dissection (Bartley et al., 2008; Xue et al., 2005). 186 
 187 
2.5.2. A. ceylanicum 188 
The experimental procedure was carried out as described recently (Tritten et al., in 189 
press-b). Briefly, the fecal egg burden was established on average from days 21 and 22 p.i. 190 
On the basis of the fecal egg burden, hamsters were assigned to equally balanced treatment 191 
groups (single oral doses of 10 or 5 mg/kg tribendimidine, 10 mg/kg dADT or AdADT) or 192 
control groups (4 animals each). For combination chemotherapy studies, we first calculated 193 
approximative ED50 values of both drugs (tribendimidine 10 mg/kg and levamisole 10 mg/kg). 194 
Both drugs were then combined at a constant ED50 ratio (10 mg/kg:10 mg/kg (1ED50:1ED50); 195 
5 mg/kg:5 mg/kg (0.5ED50:05ED50) and 2.5 mg/kg:2.5 mg/kg (0.25ED50:0.25ED50)). 196 
Hamsters were treated on day 23 p.i. The complete stools over a period of 48 hours 197 
following treatment were collected from each hamster and soaked in 0.9 % NaCl. The entire 198 
sample was then carefully examined under a binocular (magnification 10-40x) and all worms 199 
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counted. Worms remaining in the gut 7 days post-treatment were collected and counted after 200 
killing the hamsters with the CO2 method. Worm burden reductions (see H. bakeri) and worm 201 
expulsion rates were calculated. The worm expulsion rates were calculated as follows: 202 
[(c/d)*100], where c is the total number of expelled worms in a treated group and d, the total 203 
worm count (expelled worms as well as worms present in gut counted following dissection) of 204 
the same group. 205 
 206 
2.6. Statistical analysis 207 
IC50s were calculated based on the median effect principle using CompuSyn (version 208 
1.0). The r value is the linear correlation coefficient of the median-effect plot, indicating the 209 
goodness of fit, hence how accurate the IC50 is (Chou, 1976). Variance in ovicidal activities 210 
was analyzed using the Fisher’s exact test (StatsDirect, version 2.4.5; StatsDirect Ltd; 211 
Cheshire, UK). Worm burden reductions and worm expulsion rates were calculated in 212 
Microsoft® Excel. The statistical significance of the worm burden reduction was evaluated 213 
with the Kruskal-Wallis test (multiple doses against control), or the Mann-Whitney U test 214 
(single dose against control), using StatsDirect.  Combination indices (CI) at IC50 and IC90 215 
were calculated for in vitro combination studies using CompuSyn. For in vivo studies, either 216 
the CI value (A. ceylanicum) or the statistical significance (Mann-Whitney test, H. bakeri) 217 
were determined.   218 
219 
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3. Results 220 
3.1. In vitro studies against H. bakeri  221 
3.1.1. Single drug assays against third-stage larvae and adults 222 
Tribendimidine was highly active against both H. bakeri third-stage larvae (IC50: 0.32 µg/ml, r 223 
= 0.85) and adult worms in vitro (IC50: 5.09 µg/ml, r = 0.95) (Table 1). dADT showed a slightly 224 
lower efficacy than tribendimidine against L3 (IC50: 0.62 µg/ml, r = 0.94) but higher activity 225 
against adults (IC50: 3.52 µg/ml, r = 0.93). Only a very low activity was observed with AdADT 226 
(both IC50s >100 µg/ml, r = 0.91 and 0.84 respectively).  227 
 228 
3.1.2. Drug combination studies against third-stage larvae 229 
Third-stage larvae were exposed simultaneously to tribendimidine and albendazole, 230 
levamisole or ivermectin (Table 1) using a fixed dose ratio based on the IC50s and 2-fold 231 
dilutions up and down. The calculated CIs for the tribendimidine-albendazole, tribendimidine-232 
levamisole and tribendimidine-ivermectin combinations were >1000, 1.20, and 9.76, 233 
respectively. Hence, all combinations tested showed antagonistic interactions (CI >1) at the 234 
fixed dose ratio.   235 
 236 
3.1.3. Ovicidal activity 237 
In the presence of tribendimidine, 99.6 % of the eggs were fully embryonated after 24 hours, 238 
while hatching was moderately reduced by 13.4 % (P=0.116), compared to the controls 239 
(Table 2). dADT achieved similar low reductions in embryonation (2 %) and hatching (12.8 240 
%) (P=0.106). AdADT had no effect on embryonation and hatching. 241 
 242 
3.2. In vitro studies against A. ceylanicum  243 
3.2.1. Single drug assays against third-stage larvae and adults 244 
Tribendimidine strongly affected A. ceylanicum third-stage larvae (IC50: 0.32 µg/ml, r = 0.89), 245 
while adult worms’ viability was only moderately reduced (IC50: 88.44 µg/ml, r = 0.83) (Table 246 
1). A similar effect was observed for dADT, which exhibited excellent activity against L3 but 247 
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not against the adults (IC50s: 0.14 µg/ml, r = 0.95 and >100 µg/ml, r = 0.50, respectively). 248 
AdADT showed a moderate effect against both stages (IC50s: 70.0 µg/ml, r = 0.66 and 21.93 249 
µg/ml, r = 0.88, respectively).  250 
 251 
3.2.2. Drug combination studies against third-stage larvae 252 
Third-stage larvae were incubated with tribendimidine combined with albendazole, 253 
levamisole or ivermectin (Table 1) based on their respective IC50 values and 2-fold dilutions 254 
were carried up and down. The combination index at the IC50 value indicated synergism for 255 
the tribendimidine-levamisole combination (CI: 0.50), whereas the combinations of 256 
tribendimidine with albendazole and ivermectin were antagonistic (CIs: 2.53 and 4.21, 257 
respectively). 258 
 259 
3.2.3. Ovicidal activity 260 
Tribendimidine exerted minor, not significant, reductions of egg embryonation (7.3 %) and 261 
hatching (12.3 %) (Table 2). dADT and AdADT did not affect either egg embryonation or 262 
hatching (all P > 0.05).  263 
< Table 1: IC50s > 264 
< Table 2: ovicidal activity > 265 
 266 
3.3. In vivo studies against H. bakeri  267 
3.3.1. Monotherapy 268 
Tribendimidine achieved statistically significant worm burden reductions of 53.9 % at a 269 
treatment dose of 0.5 mg/kg, 68.6 % at 1 mg/kg, and complete elimination of worms at 2 270 
mg/kg, compared to the controls (Table 3). Comparably, 1 mg/kg and 2 mg/kg dADT resulted 271 
in significant worm burden reductions of 76.2 %, and 97.1 %, respectively. A moderate worm 272 
burden reduction of 42.9 % was observed following AdADT at 2 mg/kg (P=0.343). 273 
 274 
3.3.2. Combination chemotherapy 275 
 12 
Results obtained in combination chemotherapy experiments are shown in Table 3. 276 
Tribendimidine (0.5 and 1 mg/kg) combined with albendazole (10 mg/kg) revealed worm 277 
burden reductions of 67.1 % and 36.1 %, which was comparable to the effect produced by 278 
tribendimidine alone, or significantly weaker (P>0.05). Similarly, no increased dose response 279 
effect was observed for combinations of levamisole (1.25 mg/kg) and tribendimidine (68.7 % 280 
and 62.1 %). The highest activity of 85.8 % was observed with ivermectin (0.125 mg/kg) 281 
combined with 0.5 mg/kg tribendimidine (P=0.229). Doubling of the tribendimidine dose (1 282 
mg/kg), in combination with ivermectin resulted in a lower worm burden reduction of 41.1 % 283 
(P>0.05). Further dose effect studies with the three combinations were not done since these 284 
data showed that neither additive nor synergistic effects were present.   285 
  286 
< Table 3: in vivo H. bakeri > 287 
 288 
3.4. In vivo studies against A. ceylanicum  289 
3.4.1. Monotherapy 290 
 The worm expulsion rate and the worm burden reduction achieved administering a 10 291 
mg/kg dose of tribendimidine to A. ceylanicum infected hamsters were 63.3 % and 74.8 %, 292 
respectively (P=0.436) (Table 4). Following dADT treatment at the same dose, a worm 293 
expulsion rate of 88.5 % and a significant worm burden reduction of 87.4 % were measured, 294 
whereas AdADT had low to moderate effects against A. ceylanicum in vivo (worm expulsion 295 
rate: 6.3 %, worm burden reduction: 57.9 %, (P>0.999). 296 
 297 
3.4.2. Combination chemotherapy  298 
 Based on our in vitro findings, only the combination of tribendimidine and levamisole 299 
was further studied in vivo, using a fixed dose ratio based on the approximate ED50 doses of 300 
both drugs and diluted twice (10 mg/kg : 10 mg/kg, 5 mg/kg : 5 mg/kg, 2.5 mg/kg : 2.5 301 
mg/kg). These combination treatments achieved worm burden reductions of 92.7 %, 70.1 % 302 
and 3.6 %, respectively (Table 4). The calculated CI revealed an additive effect tending 303 
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towards synergism, with a CI of 1.02 at the ED50 and a CI of 0.19 at the ED90. Figure 1 304 
illustrates this finding using an isobologram.  305 
 306 
< Table 4: in vivo A. ceylanicum > 307 
< Figure 1: isobologram > 308 
309 
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Discussion 310 
 Since chemotherapy is the current mainstay for treatment of soil-transmitted 311 
helminthiases, there is a pressing need for increased efforts on drug research. Since the 312 
drug discovery and development process is extremely long and expensive (Dickson and 313 
Gagnon, 2004), combining existing marketed drugs is a powerful strategy for avoiding the 314 
spread of drug resistance and for obtaining efficacy against a broader range of parasites 315 
(Smith, 1990a, b; Smith et al., 1999). 316 
Tribendimidine, a Chinese amidantel derivative, has shown activity against a wide range of 317 
helminths maintained in rodents such as the nematodes Necator americanus, 318 
Nippostrongylus braziliensis, Strongyloides ratti, and Toxocara canis and the trematodes 319 
Clonorchis sinensis and Opisthorchis viverrini (Keiser et al., 2007; Keiser et al., 2008; Xiao et 320 
al., 2005). In the present work, we aimed to generate comprehensive efficacy data on 321 
tribendimidine and its metabolites dADT and AdADT against A. ceylanicum and H. bakeri, 322 
two laboratory hookworm models, in vitro and in vivo. In addition, drug combinations of 323 
tribendimidine plus standard drugs were tested. 324 
Tribendimidine is unstable in aqueous solution, and within minutes, dADT is the only active 325 
compound present (Yuan, 2008; Yuan et al., 2010). Hence, similar efficacies are expected 326 
for both compounds.  327 
In vitro, tribendimidine was highly active against both studied stages of H. bakeri (IC50s ≤ 5 328 
µg/ml), and a similar result was observed for dADT. For comparison, tribendimidine and 329 
dADT showed a higher activity against H. bakeri third-stage larvae and adults than the 330 
standard drugs albendazole and ivermectin but was less active than levamisole (Nwosu et 331 
al., 2011). 332 
However, while tribendimidine and dADT were highly active against A. ceylanicum L3 the 333 
drugs were only moderately active against adult A. ceylanicum (IC50s ≥ 88.5 µg/ml), 334 
suggesting some stage-specificity. It has been proposed that the presence of different 335 
nAChR subunit populations varies during the different A. caninum life-cycle stages, resulting 336 
in altered degrees of susceptibility to drugs of the nAChR group (Kopp et al., 2008b; Kotze et 337 
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al., 2009). Putting the findings obtained with tribendimidine against A. ceylanicum in context 338 
with findings from previous work shows that tribendimidine and dADT displayed a higher 339 
activity against L3 and adults than albendazole and levamisole. Adult worms were more 340 
affected by ivermectin compared to tribendimidine and its metabolites, while the effect of 341 
ivermectin on L3 was slightly lower. 342 
In both models, in contrast to albendazole which strongly inhibited embryonation and 343 
hatching (Nwosu et al. 2011; Tritten et al., in press-b), tribendimidine and its metabolites 344 
displayed no overt ovicidal activity at the tested drug concentrations.  345 
In vivo, tribendimidine cleared H. bakeri infections in mice at a dose of 2 mg/kg and reduced 346 
the worm burden by more than 50 % at 0.5 mg/kg. A comparable result was obtained with 347 
dADT, as the worm burden reduction following a 2 mg/kg treatment was of 97 %. As 348 
expected from the in vitro data, AdADT had a moderate impact on the H. bakeri worm burden 349 
(2 mg/kg dose, 42 % worm burden reduction).  350 
Roughly 75 % of A. ceylanicum worms were expelled following a 10 mg/kg treatment with 351 
tribendimidine, while 87 % were cleared by dADT at the same dose, showing the slightly 352 
better efficacy of the latter. AdADT reduced the worm burden by approximately 6 % (WER). 353 
Hence, in both models, tribendimidine and dADT displayed similar potent efficacies, both in 354 
vitro and in vivo, whereas AdADT showed only moderate activities.  355 
It is interesting to note that in a recent study worm burden reductions observed after 356 
tribendimidine oral treatments against N. americanus were significantly higher than those 357 
achieved by the metabolite dADT (Xue et al., 2010), which contradicts the findings observed 358 
in the A. ceylanicum- model and stability issues highlighted above. The efficacy of AdADT 359 
against N. americanus was moderate, in line with our results (Xue et al., 2010). Albendazole, 360 
which showed a superior efficacy over tribendimidine against A. ceylanicum in vivo (Tritten et 361 
al., in press-b), produced a less pronounced effect against N. americanus (Xue et al., 2005). 362 
Similarly, H. bakeri was less affected by albendazole (Nwosu et al., 2011). Overall, our 363 
results re-emphasize that all hookworm species show varying degrees of sensitivity to 364 
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different drugs, a phenomenon well-studied for drug effects against Ancylostoma spp. and N. 365 
americanus (Behnke et al., 1993; Xue et al., 2005).  366 
Tribendimidine combinations with albendazole, levamisole and ivermectin interacted 367 
antagonistically in vitro against H. bakeri L3 larvae. These findings were confirmed in our in 368 
vivo studies. Interestingly, increased tribendimidine doses resulted in a decreased treatment 369 
effect, particularly notable for albendazole- or ivermectin-tribendimidine combinations. On the 370 
other hand, against A. ceylanicum, additive to synergistic effects were observed with a 371 
combination of tribendimidine-levamisole in vitro and in vivo. This finding suggests that the 372 
two drugs might act via an at least partially different mechanism, perhaps at different nAChR 373 
subunits. Initially, it had been proposed that tribendimidine also belongs to the L-type nAChR 374 
agonists group and shares the same mode of action as levamisole. On the other hand, it was 375 
noticed that tribendimidine does not behave like a typical nAChR agonist (levamisole or 376 
pyrantel), acting more rapidly, and paralyzing the worms starting from the head (Hu et al., 377 
2009). It might be important to note that levamisole was shown to have a broad range of 378 
immunomodulatory effects in rodents and humans. In anti-cancer chemotherapy, levamisole 379 
is thought to potentiate the combined drug 5-fluorouracil (Mitchell, 2003; Stevenson et al., 380 
1991). Possibly, these immunomodulatory properties play a role in the additive to synergistic 381 
interaction with tribendimidine. Though not tested here we would have expected a similar 382 
nature of interaction combining dADT with levamisole, since these drugs have comparable 383 
efficacies and are structurally very close. 384 
In conclusion, tribendimidine and dADT show potent anti-hookworm properties, when 385 
administered alone, in single oral doses. We have confirmed that the H. bakeri mouse model 386 
is an excellent laboratory model to study drug effects on hookworms. Since H. bakeri can be 387 
maintained in mice and worms have matured already 14 days post-infection this model is fast 388 
and cost-effective. Promisingly, the combination tribendimidine-levamisole revealed excellent 389 
efficacy (synergism at the ED90), against A. ceylanicum. This combination should therefore 390 
be investigated in further detail, i.e. in drug interaction studies and against other soil-391 
transmitted helminths.  392 
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Table 1. Activity of tribendimidine, dADT and AdADT and tribendimidine combinations 520 
against H. bakeri and A. ceylanicum in vitro 72 hours post-incubation. 521 
 522 
 523 
IC50: Fifty-percent inhibitory concentrations. For comparison, IC50 values of albendazole, 524 
levamisole and ivermectin are shown #(Nwosu et al., 2011) § (Tritten et al., in press-b) 525 
CI at IC50 = combination index at IC50. CI <1: synergism; CI =1: additive effect; CI >1: 526 
antagonism. n.d. = not determined (no fitting possible).  527 
r = linear correlation coefficient of the median-effect plot, indicating the goodness of fit. (r ≥ 528 
85 indicates a satisfactory fit).529 
 H. bakeri IC50s (r) A. ceylanicum  IC50s (r) 
Drug L3 Adults L3 Adults 
Tribendimidine 0.32 (0.85) 
(0.85) 
5.09 (0.95) 0.32 (0.89) 88.44 (0.83) 
dADT 0.62 (0.94) 3.52 (0.93) 0.14 (0.95) > 100 (0.50) 
AdADT > 100 (0.91) 
100 
> 100 (0.84) 
(00)((((0.84) 
70.0 (0.66) 21.93 (0.88) 
Albendazole
 
9.05
#
 > 100 (n.d.) 32.4 (0.87)
§
 > 100 (0.77)
§
 
Levamisole-HCl
 
0.02
#
 0.56 (0.70) 1.6 (0.95)
§
 > 100 (0.79)
§
 
Ivermectin
 
6.92
#
 > 100 (n.d.) 1.15 (0.88) 1.22 (0.89) 
CI at IC50 Tribendimidine-Albendazole > 1000
 
n.d. 2.53 n.d. 
CI at IC50 Tribendimidine-Levamisole 1.20 n.d. 0.50 n.d. 
CI at IC50 Tribendimidine-Ivermectin 9.76 n.d. 4.21 n.d. 
 24 
Table 2. Ovicidal activity (embryonation and hatching) of tribendimidine, dADT and 530 
AdADT at a concentration of 10 µg/ml.  531 
 532 
 533 
 534 
 535 
SD = standard deviation, * P<0.001  536 
 537 
538 
 H. bakeri A. ceylanicum 
Group % Embryonation 
(SD) 
% Hatching (SD) % Embryonation 
(SD) 
% Hatching (SD) 
Control 100 (1.3) 100 (2.9) 100 (3.5) 100 (9.8) 
Tribendimidine 99.6 (2.1) 86.6 (10.6) 92.7 (10.0) 87.7 (22.4) 
dADT 98.0 (3.6) 87.2 (0.8) 100 (2.7) 100 (4.4) 
AdADT 100 (0) 98.4 (5.6) 100 (5.8) 100 (3.0) 
 25 
Table 3: Dose-response relationships of tribendimidine, dADT and AdADT 539 
administered to H. bakeri-infected mice.  540 
 541 
 542 
 543 
SD= standard deviation. NA= Not assessed.  544 
The numbers in superscript refer to the corresponding control group. α versus tribendimidine 545 
0.5 mg/kg, β  versus tribendimidine 1 mg/kg. # For comparison, worm burden reductions 546 
obtained with the subcurative doses of the partner drugs (albendazole, levamisole, 547 
ivermectin) are also listed (Nwosu et al., 2011) 548 
549 
Group Dose 
(mg/kg) 
Mean 
number of 
worms after 
7 days (SD) 
Worm 
burden 
reduction 
(%) 
P-value 
Control 1 – 26.25 (9.9) – – 
Control 2 – 109.5 (74.1) – – 
Control 3 – 32.75 (14.7) – – 
Tribendimidine 0.5
2 
 50.5 (36.5) 53.9 0.006 
1
1 
8.25 (3.6) 68.6 
2
1 
0.0 (0.0) 100 
dADT 1
1 
6.25 (8.8) 76.2 0.010 
2
1 
0.75 (1.0) 97.1 
AdADT 2
1 
15.0 (12.8) 42.9 0.343 
Albendazole
 #
 10 – 52.6 NA 
Levamisole-HCl 
#
 1.25
 
– 61.5 NA 
Ivermectin 
#
 0.125 – 53.7 NA 
Combination Tribendimidine-Albendazole
  
0.5 + 10
2 
36.0 (32.2) 67.1 0.486
α
 
Combination Tribendimidine-Albendazole
  
1 + 10
3
 70.0 (40.3) 36.1 0.057
β
 
Combination Tribendimidine-Levamisole
 
0.5 + 1.25
2 
34.25 (25.7) 68.7 0.686
α
 
Combination Tribendimidine-Levamisole
 
1 + 1.25
3 
41.5 (65.2) 62.1 0.543
β
 
Combination Tribendimidine-Ivermectin
 
0.5 + 0.125
2 
15.5 (17.1) 85.8 0.229
α
 
Combination Tribendimidine-Ivermectin 1 + 0.125
3
 64.5 (55.1) 41.1 > 0.05
β
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Table 4: Dose-response relationships of tribendimidine, dADT and AdADT 550 
administered to A. ceylanicum-infected hamsters.  551 
 552 
 553 
SD= standard deviation. NA=Not assessed. The numbers in superscript refer to the 554 
corresponding control group. P-value determined for worm burden reductions.  CI at IC50 = 555 
combination index at IC50, CI at IC90 = combination index at IC90. CI <1: synergism; CI =1: 556 
additive effect; CI >1: antagonism. § The worm expulsion rate and the worm burden reduction 557 
obtained with 10 mg/kg levamisole are given (Tritten et al., in press-b).  558 
 559 
Figure legend 560 
Figure 1: Isobologram for the combined effect of tribendimidine and levamisole.  561 
Fa= effect level.  562 
Group Dose 
(mg/kg) 
Mean 
number of 
worms (SD) 
Mean 
number of 
expelled 
worms (SD) 
Worm 
expulsion 
rate (%) 
Worm 
burden 
reduction 
(%) 
P-value 
Control 1 – 18.0 (18.2) 0.5 (0.8) 2.8 – – 
Control 2 – 13.8 (8.0) 0 0 – – 
Tribendimidine 5
1  
17 (16.7) 3.8 (4.9) 22.1 25.7 0.436 
10
1  
 12.3 (6.5) 7.8 (5.3) 63.3  74.8 
dADT 5
1 
13.8 (7.3) 7.5 (8.7) 54.5 64.9 0.023 
10
1 
19.5 (9.3) 17.3 (8.6) 88.5  87.4 
AdADT 5
1 
19.3 (11.3) 0.5 (1) 2.6 0 > 0.999 
10
1 
8.0 (3.4) 0.5 (0.6) 6.3  57.9 
Levamisole-HCl 
§
 10
 
– – 44.3 60.2 NA 
Combination 
Tribendimidine-Levamisole 
10+10
2 
8.7 (5.7) 7.7 (6.0) 88.5 92.7 CI at IC50= 1.02 
CI at IC90= 0.19 5+5
2 
13.3 (11.8) 9.3 (11.2) 70.0 70.1 
2.5+2.5
2 
19.3 (15.1) 6.0 (3.3) 31.2 3.6 
